›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:LiquidHALLMARK®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
LucenceType:
Laboratory Developed Test
Related tests:
LiquidHALLMARK is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. Requiring only a simple blood sample, LiquidHALLMARK is a broad biomarker panel that is quicker and less invasive compared to tissue biopsies. LiquidHALLMARK examines plasma circulating tumor DNA (ctDNA) mutations in 80 genes, including fusions in 10 genes.
Cancer:
Breast Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Carcinoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Urothelial Cancer
Gene:
ABL1 (ABL proto-oncogene 1), AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), BRAF (B-raf proto-oncogene)
See More ...
ABL1 (ABL proto-oncogene 1), AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CDH1 (Cadherin 1), CDK6 (Cyclin-dependent kinase 6), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), EGFR (Epidermal growth factor receptor), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FBXW7 (F-Box And WD Repeat Domain Containing 7), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FLT3 (Fms-related tyrosine kinase 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAPK1 (Mitogen-activated protein kinase 1), MET (MET proto-oncogene, receptor tyrosine kinase), NOTCH1 (Notch 1), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TP53 (Tumor protein P53), U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), VHL (von Hippel-Lindau tumor suppressor), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
Confirmatory trial(s)
Confirmatory trial(s)
